Half-year results have been released
New investment approach in life science
Stay up-to-date with Pharma Equity Group A/S news and developments. By subscribing, you’ll be among the first to hear about exciting new investment opportunities, the development of our portfolio company Reponex Pharmaceuticals and important company announcements. To sign up, simply press the header or the button below and enter your email address in the subscription box on the page. Accept the validation mail, which is sent to your email right after signing up. We look forward to keeping you informed and engaged with the latest news from Pharma Equity Group A/S.
Presentation and valuation of Pharma Equity Group (PEG) - 30.05.2023
HC Andersen Capital has reviewed PEG and has created a 1-pager on it. In their review, they include a description of the company and what drives the value of PEG. HC Andersen Capital also looks at 3 different scenarios for the value of the company. In their base case scenario, they calculate a value of DKK 1.7 billion. dkr.
Who is Pharma Equity Group?
The indirect official listing of Reponex Pharmaceuticals A/S increases the Pharma Equity Group’s flexibility to fund potential acquisitions by using new shares as funding through equity funding by means of future issuances of new shares, with or without pre-emptive rights for existing shareholders, as payment.
It is Pharma Equity Groups’ ambition to focus on life sciences companies who have clinical candidates in their portfolio that are in an early stage of development (before phase II). The strategy is to bring the different possible target companies, with each individual clinical programs, to a clinical phase II stage at which the effect of the clinical candidates can be documented with relevant clinical data and secured IP. In this phase Pharma Equity Group will initiate its strategy on partnering, focusing on companies that have complementary sizes or functional areas of strength and capabilities.
Pharma Equity Group have a constant focus on creating the right starting point for the implementation of an exclusive outlicencing of the company’s clinical candidates to global pharma companies that can contribute to the further clinical and regulatory process as well as represent relevant distribution power.
Pharma Equity Group has the objective of being organizationally effective in all the invested companies. This means that each of the invested companies has adopted an aggressive commercial outsourcing strategy to be as agile as possible to meet a complex and continually changing pharmaceutical industry. The strategy creates cost-effectiveness and the flexibility to scale up or down rapidly with respect to relevant human knowledge resources needed, which the company considers to be a key factor and driver of success.